Author Archives: Vanda Pinto

How Nerve Cells Damaged at Disease Onset Goal of EU Project

An almost €2 million (about $2.3 million) EU-funded project is advancing the understanding of how damaged or abnormal cell parts are removed at the synapses, a process known as synapse-specific autophagy, and how defects in this mechanism contribute to neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s. Synapses,…

Grants Given to 8 ‘Blue Sky’ Research Projects at Emory, Georgia Tech

Eight grants worth a total of $575,000 were awarded by the McCamish Parkinson’s Disease Innovation Program to research teams at Georgia Tech and Emory University advancing projects into Parkinson’s disease. “These grants are specifically focused on technology-driven research for understanding, treating, and curing Parkinson’s disease,” Garrett Stanley, PhD, professor…

Way of Protecting Key Neurons in LRRK2-linked Parkinson’s Seen

In mice with a harmful mutation in the leucine-rich repeat protein kinase 2 (LRRK2) gene, one of the most common genetic causes of Parkinson’s disease, treatment with a small molecule compound restored the recycling of damaged mitochondria — the cells’ powerhouses — from dopamine-producing nerve cells. A failure…

Trial of Microbiota Transplant in Treating Patients Opens in Australia

BiomeBank is launching a trial in Australia to test whether its fecal microbiota transplantation therapy, which works to replenish gut bacteria, is a safe, tolerable and effective treatment of Parkinson’s disease symptoms, such as constipation. The trial is being conducted in collaboration with the Royal Adelaide and Queen Elizabeth hospitals…

NRG Awarded $500K by MJFF to Develop Disease-modifying Therapy

NRG Therapeutics has been awarded a $500,000 grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of its potential disease-modifying therapy for Parkinson’s. That funding will go toward investigating how small molecules, developed by NRG, inhibit the opening of mitochondrial pores, known…

New Psychedelic Therapy AKO004 Under Development by Akome

A new psychedelic drug formulation called AKO004 is now under development by Akome Biotech, a wholly owned subsidiary of Core One Labs, as a potential treatment for Parkinson’s disease. The company has filed a provisional patent application for AKO004 with the U.S. Patent and Trademark Office. The AKO004…

Acupuncture as Add-on Therapy May Further Ease Disease Symptoms

People with Parkinson’s disease who combine standard medication with various types of acupuncture treatments may see improvements in their motor function and quality of life, a review study from China suggests. However, its researchers noted that additional clinical trials are necessary to validate these findings. The study, “Acupuncture-Related…

Study Explores Therapeutic Potential of Hc-TeTx

A potential mechanism by which Hc-TeTx — a fragment of the tetanus toxin previously shown to have neuroprotective effects — enters the central nervous system (CNS) has been unraveled by researchers in Spain. Hc-TeTx appears to mimic a neurotrophin called brain-derived neurotrophic factor (BDNF). Neurotrophins are proteins that promote the…

‘Robust’ Genetic Patient Data Open to Researchers via Fox DEN

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe are opening “robust” genetic data to researchers worldwide that could help in identifying markers of treatment response and disease progression, and ultimately may lead to better therapies for Parkinson’s disease. These new and de-identified (for privacy)…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums